Among patients with non-CCC gynecological disease (n = 239), TFPI2 levels > 345 pg/mL were observed in five patients with benign ovarian tumors (3 EMS and 2 non-EMS), 13 patients with non-CCC subtype EOCs (7 serous, 3 endometrioid, 1 mucinous, and 2 other-subtypes), and 5 patients with uterine disease (2 cervical cancer, 3 endometrioid endometrial cancer) (S1 Table). This evidence concerns the gene TFPI2 and female reproductive system disorder.